GGrantIndex
← Leaderboards

Lilie Leming Lin

University Of Tx Md Anderson Can Ctr

$2,171,805
Attributed
$5,842,669
Total exposure
3
Grants
2
Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.

Funding over time

peak $1.5M · FY202125
$2M$1.5M$1M$500K$0
'21
'22
'23
'24
'25

Funding mix

By agency

NIH$5,842,669 · 3

By mechanism

R01$5,842,669 · 3

Most similar at University Of Tx Md Anderson Can Ctr

Same institution · by research overlap

Others in their field

Other Emerging Leaders on “Cancer Center

Research focus

Cancer CenterTumorToxic EffectMalignant NeoplasmsCancer PatientFutureSiteClinical DataNovel TherapeuticsDiagnosisBiological MarkersMulticenter TrialsIn VivoImageImaging BiomarkerMalignant Breast NeoplasmBindingDefectClinical TrialsHomologous RecombinationAutoradiographyEpigenetic ProcessCancer TherapyCells

Grant awards (13)

The Impact of Biologic Aging on Immunity-Related Cervical Cancer Outcome Disparities Among Women Living with HIV in Zambia$663,373
R01 · FY2025 · CA · contact PI
Breast Cancer PARP PET Imaging AIP to Support FDA Approval & Commercialization$538,647
R01 · FY2025 · CA
The Impact of Biologic Aging on Immunity-Related Cervical Cancer Outcome Disparities Among Women Living with HIV in Zambia$69,565
R01 · FY2025 · CA · contact PI
The Impact of Biologic Aging on Immunity-Related Cervical Cancer Outcome Disparities Among Women Living with HIV in Zambia$27,888
R01 · FY2025 · CA · contact PI
The Impact of Biologic Aging on Immunity-Related Cervical Cancer Outcome Disparities Among Women Living with HIV in Zambia$760,825
R01 · FY2024 · CA · contact PI
Breast Cancer PARP PET Imaging AIP to Support FDA Approval & Commercialization$538,137
R01 · FY2024 · CA
The Impact of Biologic Aging on Immunity-Related Cervical Cancer Outcome Disparities Among Women Living with HIV in Zambia$666,443
R01 · FY2023 · CA · contact PI
Breast Cancer PARP PET Imaging AIP to Support FDA Approval & Commercialization$597,988
R01 · FY2023 · CA
A novel PARP inhibitor PET tracer for breast cancer$222,661
R01 · FY2023 · CA · contact PI
Breast Cancer PARP PET Imaging AIP to Support FDA Approval & Commercialization$601,217
R01 · FY2022 · CA
A novel PARP inhibitor PET tracer for breast cancer$259,772
R01 · FY2022 · CA · contact PI
Breast Cancer PARP PET Imaging AIP to Support FDA Approval & Commercialization$631,080
R01 · FY2021 · CA
A novel PARP inhibitor PET tracer for breast cancer$265,073
R01 · FY2021 · CA · contact PI